- Home
- SGN vs ALZN Comparison
SGN vs ALZN Comparison
Compare SGN & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGN
- ALZN
- Stock Information
- Founded
- SGN 2019
- ALZN 2016
- Country
- SGN United States
- ALZN United States
- Employees
- SGN N/A
- ALZN N/A
- Industry
- SGN
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- SGN
- ALZN Health Care
- Exchange
- SGN Nasdaq
- ALZN Nasdaq
- Market Cap
- SGN 7.8M
- ALZN 8.2M
- IPO Year
- SGN 2023
- ALZN 2021
- Fundamental
- Price
- SGN $1.75
- ALZN $2.34
- Analyst Decision
- SGN
- ALZN Strong Buy
- Analyst Count
- SGN 0
- ALZN 1
- Target Price
- SGN N/A
- ALZN $42.00
- AVG Volume (30 Days)
- SGN 308.0K
- ALZN 176.1K
- Earning Date
- SGN 11-13-2025
- ALZN 09-10-2025
- Dividend Yield
- SGN N/A
- ALZN N/A
- EPS Growth
- SGN N/A
- ALZN N/A
- EPS
- SGN N/A
- ALZN N/A
- Revenue
- SGN $391,126.00
- ALZN N/A
- Revenue This Year
- SGN N/A
- ALZN N/A
- Revenue Next Year
- SGN N/A
- ALZN N/A
- P/E Ratio
- SGN N/A
- ALZN N/A
- Revenue Growth
- SGN N/A
- ALZN N/A
- 52 Week Low
- SGN $0.44
- ALZN $2.06
- 52 Week High
- SGN $13.72
- ALZN $17.10
- Technical
- Relative Strength Index (RSI)
- SGN 46.22
- ALZN 43.73
- Support Level
- SGN $1.67
- ALZN $2.33
- Resistance Level
- SGN $2.08
- ALZN $2.62
- Average True Range (ATR)
- SGN 0.14
- ALZN 0.11
- MACD
- SGN -0.03
- ALZN 0.01
- Stochastic Oscillator
- SGN 8.67
- ALZN 8.33
About SGN Signing Day Sports Inc.
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.